(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ZEAL & ZEALAND PHARMA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

ZEAL & ZEALAND PHARMA

ST13

US500000090144485

Classe

5, 10, 16, 35, 41, 42, 44, 45

Pedido

90144485

Registro

6986947

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

52

Atualização mais recente

24/02/2023

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5, 10, 16, 35, 41, 42, 44, 45

Data de depósito

28/08/2020

Data de registro

21/02/2023

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

21/02/2023

Última transação

24/02/2023

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use

Primeiro uso

2021-06-00

Primeiro uso no comércio

2021-06-00

Código do desenho

3

Tipo de titular

99

Localização do titular

Søborg, DK

Examinador

VENGURLEKAR, SAGAR S

Unidade examinadora

M80

Localização atual

PUBLICATION AND ISSUE SECTION

Descrição da marca

The mark consists of the wording "ZEAL&" with each letter appearing in white, in a blue circle, an overlapped grey circle, an overlapped yellow circle, an overlapped turquoise circle, a red circle, from left to right, with the grey wording "ZEALAND PHARMA" written below.

Titulares e representantes

Titulares

Zealand Pharma A/S

Representantes

Shannon Marie McKeon DYKEMA GOSSETT PLLC

Classificação técnica

Classes Nice

Classe 5Classe 10Classe 16Classe 35Classe 41Classe 42Classe 44Classe 45

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

(Based on 44(e)) Pharmaceutical preparations for the treatment of diabetes, obesity and gastrointestinal diseases; synthetic peptides for pharmaceuticals purposes for the treatment of diabetes, obesity and gastrointestinal diseases; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, namely, pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes containing insulin or glucagon or analogues of those

Classe 10

(Based on Use in Commerce) Medical apparatus and instruments, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; blood glucose monitors for medical purposes; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods; wearable health devices for insulin monitoring

Classe 16

(Based on Use in Commerce) printed pharmaceutical information leaflets in the field of diabetes, obesity and gastrointestinal diseases; printed publications, namely, books, magazines, periodicals and manuals, all in the field of diabetes, obesity and gastrointestinal diseases; printed instructional or teaching matter in the field of diabetes, obesity and gastrointestinal diseases; printed instructional and teaching materials about diagnosing and treatment of diabetes, obesity and gastrointestinal diseases; printed guidelines for diagnosing and treatment of diabetes, obesity and gastrointestinal diseases

Classe 35

(Based on 44(e)) Marketing services; customer relationship management; business administrative services for medical referrals; patient relationship management services; business administration of pharmacy and pharmaceutical benefit plans

Classe 41

(Based on Use in Commerce) Publication of articles and scientific text and posters featuring the results of clinical trials for pharmaceutical preparations related to diabetes, obesity and gastrointestinal diseases; providing educational seminars, educational exhibitions, conferences and training courses, all in the field of diabetes, obesity and gastrointestinal diseases; educational seminars, educational exhibitions, conferences and instructional services relating to medical treatments in the field of diabetes, obesity and gastrointestinal diseases; educational services, namely, organizing and conducting educational programs, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity and gastrointestinal diseases

Classe 42

(Based on 44(e)) Scientific and technological services, namely, research and design in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; providing websites featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely, providing a website featuring technology that enables users to obtain data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases

Classe 44

(Based on 44(e)) Medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; clinical trials; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing web-based on-line portals that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely, providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid

Classe 45

(Based on 44(e)) Licensing of patent and intellectual property rights arising from medical and pharmaceutical research and development activities; licensing of proprietary intellectual property

Publicações

Histórico de despachos e eventos da marca no USPTO.

52 publicações encontradas

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

21/02/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

21/02/2023

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

14/01/2023

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

13/01/2023

DOCK

ASSIGNED TO EXAMINER

17/12/2022

SUPC

STATEMENT OF USE PROCESSING COMPLETE

15/11/2022

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

15/11/2022

IUAF

USE AMENDMENT FILED

27/10/2022

EISU

TEAS STATEMENT OF USE RECEIVED

27/10/2022

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

23/06/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

09/06/2022

EX1G

SOU EXTENSION 1 GRANTED

07/06/2022

EXT1

SOU EXTENSION 1 FILED

07/06/2022

EEXT

SOU TEAS EXTENSION RECEIVED

07/06/2022

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

04/02/2022

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

14/12/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

19/10/2021

PUBO

PUBLISHED FOR OPPOSITION

19/10/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

29/09/2021

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

13/09/2021

ALIE

ASSIGNED TO LIE

12/09/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/09/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

11/09/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

11/09/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

11/09/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

11/09/2021

ZZZX

PREVIOUS ALLOWANCE COUNT WITHDRAWN

09/09/2021

PBCR

WITHDRAWN FROM PUB - OG REVIEW QUERY

07/09/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

24/08/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

24/08/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

24/08/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

24/08/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

24/08/2021

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

05/08/2021

GNFR

FINAL REFUSAL E-MAILED

05/08/2021

CNFR

FINAL REFUSAL WRITTEN

05/08/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/08/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/08/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/08/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

27/07/2021

GNRT

NON-FINAL ACTION E-MAILED

27/07/2021

CNRT

NON-FINAL ACTION WRITTEN

27/07/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

25/06/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

25/06/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

25/06/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

07/01/2021

GNRT

NON-FINAL ACTION E-MAILED

07/01/2021

CNRT

NON-FINAL ACTION WRITTEN

07/01/2021

DOCK

ASSIGNED TO EXAMINER

30/12/2020

MDSM

NOTICE OF DESIGN SEARCH CODE E-MAILED

02/10/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/10/2020

NWAP

NEW APPLICATION ENTERED

01/09/2020

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ZEAL & ZEALAND PHARMA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.